Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Clinical Trials
1.5k
Trial Phases
5 Phases
Drug Approvals
70
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
Clinical Trials
Distribution across different clinical trial phases (1398 trials with phase data)• Click on a phase to view related trials
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Other: Placebo
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 723
- Registration Number
- NCT07088068
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
- Conditions
- Autoimmune Haemolytic Anaemia
- Interventions
- Drug: placebo
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT07086976
- Locations
- 🇩🇰
Investigational Site Number : 2080002, Copenhagen, Denmark
🇮🇱Investigational Site Number : 3760002, Tel Aviv, Israel
🇯🇵Investigational Site Number : 3920015, Fukuoka-shi, Japan
Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age
- Conditions
- Respiratory Syncytial Virus Immunization
- Interventions
- Biological: RSV vaccine formulation 1 doseBiological: RSV vaccine formulation 3 doseBiological: RSV vaccine formulation 8 doseBiological: RSV vaccine formulation 2 doseBiological: RSV vaccine formulation 4 doseBiological: RSV vaccine formulation 6 doseBiological: RSV vaccine formulation 7 doseBiological: RSV vaccine formulation 5 dose
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 240
- Registration Number
- NCT07071558
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 218
- Registration Number
- NCT07053423
Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 350
- Registration Number
- NCT07052396
- Prev
- 1
- 2
- 3
- 4
- 5
- 295
- Next
News
Kling Bio Partners with Sanofi to Develop Next-Generation Antiviral Antibodies Using Proprietary B Cell Platform
Kling Bio has entered into a collaboration and license option agreement with Sanofi to discover neutralizing antibodies against a clinically relevant human viral pathogen using its Kling-Select platform.
Sanofi Acquires Vicebio for $1.15 Billion to Expand Respiratory Vaccine Pipeline with Molecular Clamp Technology
Sanofi announced plans to acquire London-based biotechnology company Vicebio for $1.15 billion in cash, with potential milestone payments up to $450 million based on development achievements.
Omega Funds Closes Oversubscribed $647M Fund VIII to Accelerate Life Sciences Innovation
Omega Funds successfully closed its eighth fund with $647 million in capital commitments, exceeding its $600 million target despite challenging fundraising conditions.
Trogenix Strengthens Leadership Team with Key Clinical Appointments as Odysseus Platform Advances Toward Clinical Trials
Trogenix has appointed Atif Abbas, MD as Chief Medical Officer, bringing over 25 years of oncology drug development experience including successful IND submissions for immunotherapy compounds and regulatory approvals.
Thermo Fisher Scientific Acquires Sanofi's New Jersey Manufacturing Site to Expand U.S. Sterile Drug Production
Thermo Fisher Scientific will acquire Sanofi's sterile manufacturing facility in Ridgefield, New Jersey, expanding their strategic partnership to enhance U.S. drug product manufacturing capacity.
Sanofi's SAR446597 Gene Therapy Receives FDA Fast Track Designation for Geographic Atrophy Treatment
The US FDA has granted fast track designation to Sanofi's SAR446597, a one-time intravitreal gene therapy for treating geographic atrophy due to age-related macular degeneration.
Cipla Plans Entry into India's Weight Management Market as Obesity Becomes Strategic Priority
Cipla is preparing to enter India's weight management segment to address rising demand for effective obesity solutions, as announced by CEO Umang Vohra in the company's 2024-25 annual report.
IL-2 Inhibitor Pipeline Expands with 20+ Companies Developing 22+ Therapeutic Candidates
DelveInsight's 2025 pipeline report reveals over 20 pharmaceutical companies are actively developing 22+ interleukin-2 inhibitor drugs across various clinical stages.
Renasant Bio Raises $54.5M to Develop Novel Ion Channel Therapies for ADPKD
Renasant Bio secured $54.5 million in seed funding from investors including 5AM Ventures, Atlas Venture, OrbiMed and Qiming Venture Partners USA to develop treatments for autosomal dominant polycystic kidney disease (ADPKD).
Sanofi Advances Multiple Phase 2 Trials Targeting Rare Kidney Diseases and Ulcerative Colitis
Sanofi has initiated a Phase 2a clinical trial evaluating three experimental drugs—Frexalimab, SAR442970, and Rilzabrutinib—for treating primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) in patients aged 16 to 75 years.